NCT04802590 2026-03-04
Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma
The Lymphoma Academic Research Organisation
Phase 2 Active not recruiting
Clinical Trials
37 trialsNCT07217938 2026-03-03
TRADstat
Peter MacCallum Cancer Centre, Australia
Phase 2 Recruiting
NCT07292207 2025-12-18
ARCHE
Nagoya City University
Phase 2 Not yet recruiting
NCT05559164 2025-11-14
Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted
Rutgers, The State University of New Jersey
Phase 2 Recruiting
NCT05392608 2025-09-17
SEQUEL-Breast
Borstkanker Onderzoek Groep
Phase 2 Active not recruiting
NCT06033092 2025-08-28
TOLERANT
European Institute of Oncology
Phase 2 Active not recruiting
NCT06150898 2025-06-13
KePreSt
Jules Bordet Institute
Phase 2 Recruiting
NCT05247268 2025-04-06
Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer
Fudan University
Phase 2 Recruiting
NCT02852486 2025-03-30
EDI-PIO
University of Campinas, Brazil
Phase 2 Completed
NCT04717700 2025-03-18
SABLe
Odense University Hospital
Phase 2 Active not recruiting
NCT04722575 2025-03-13
NEO-TIM
Fondazione Melanoma Onlus
Phase 2 Active not recruiting
NCT06275919 2025-03-13
MIRAGE
Istituto Oncologico Veneto IRCCS
Phase 2 Recruiting
NCT04503694 2025-03-05
REGINA
Jules Bordet Institute
Phase 2 Recruiting
NCT04554459 2024-08-14
Pona-CELL
Institute of Hematology and Blood Transfusion, Czech Republic
Phase 2 Terminated
NCT05163106 2024-08-02
NEOLETRIB
University Hospital, Akershus
Phase 2 Completed
NCT05265988 2024-07-31
MERIDIAN
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Phase 2 Completed
NCT04243122 2024-05-29
AIRPORT-MPN
Ottawa Hospital Research Institute
Phase 2 Completed
NCT06229067 2024-01-29
Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT05370807 2023-10-24
RegoMel
Universitair Ziekenhuis Brussel
Phase 2 Unknown
NCT03086538 2022-06-15
Pemetrexed Plus Tarceva as Salvage Treatment in EGFR Overexpressed Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy
Samsung Medical Center
Phase 2 Completed
NCT02897050 2022-04-20
Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Suspended
NCT04389073 2022-02-25
Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Unknown
NCT02045017 2021-08-27
Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency
Celgene
Phase 2 Completed
NCT03448731 2020-04-08
DERMIA
Fundacion CRIS de Investigación para Vencer el Cáncer
Phase 2 Completed
NCT04242927 2020-04-01
A Study to Investigate Nicotinic Acid on VEGFR Inhibitor-Associated Hand-Foot Skin Reactions
First People's Hospital of Hangzhou
Phase 2 Unknown
NCT03159845 2020-01-07
ZENITH
Azienda Ospedaliero, Universitaria Pisana
Phase 2 Completed
NCT03024580 2019-08-15
MEGA
Instituto Nacional de Cancer, Brazil
Phase 2 Unknown
NCT03405168 2018-11-16
Routine Therapy Plus Moxifloxacin in Advanced Breast Cancer
Sun Yat-sen University
Phase 2 Completed
NCT03259919 2018-10-18
pilPregMet
Norwegian University of Science and Technology
Phase 2 Completed
NCT02978547 2018-01-18
Metformin 001
British Columbia Cancer Agency
Phase 2 Unknown
NCT01943864 2017-05-31
A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract Cancers
GlaxoSmithKline
Phase 2 Completed
NCT02756663 2016-11-08
PANORAMA-5
Novartis
Phase 2 Withdrawn
NCT01563055 2015-08-10
A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia
GlaxoSmithKline
Phase 2 Completed
NCT01808326 2015-06-22
A Phase II, Open Label, Single Arm, Multicenter Study of Chlorambucil in Japanese Previously Untreated Patients With Chronic Lymphocytic Leukemia
GlaxoSmithKline
Phase 2 Completed
NCT00086203 2015-03-25
Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)
FDA Office of Orphan Products Development
Phase 2 Completed
NCT00080080 2007-06-08
Study of Talabostat and Docetaxel in Advanced Non-Small Cell Lung Cancer
Point Therapeutics
Phase 2 Completed
NCT00083239 2007-06-08
Study of Talabostat in Advanced Melanoma
Point Therapeutics
Phase 2 Completed